Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction
| Autor: | M. V. Vatsik-Gorodetskaya, Zh. D. Kobalava, A. A. Shavarov |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
apixaban Renal function RM1-950 urologic and male genital diseases Amiodarone Dabigatran Internal medicine medicine Diseases of the circulatory (Cardiovascular) system atrial fibrillation dabigatran Pharmacology (medical) rivaroxaban Stroke amiodarone glomerular filtration rate Rivaroxaban business.industry Atrial fibrillation medicine.disease RC666-701 Cardiology Apixaban Therapeutics. Pharmacology Cardiology and Cardiovascular Medicine business medicine.drug Kidney disease |
| Zdroj: | Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 17, Iss 1, Pp 62-72 (2021) |
| ISSN: | 2225-3653 1819-6446 |
| DOI: | 10.20996/1819-6446-2021-02-03 |
| Popis: | Atrial fibrillation and renal dysfunction often coexist, each disorder may predispose to the other and contribute to worsening prognosis. Both atrial fibrillation and chronic kidney disease are associated with increased risk of stroke and thromboembolic complications. Oral anticoagulation for stroke prevention is therefore recommended in patients with atrial fibrillation and decreased renal function. Each direct oral anticoagulant has unique pharmacologic properties of which clinician should be aware to optimally manage patients. The doses of direct oral anticoagulants require adjustment for renal function. There is debate regarding which equation, the Chronic Kidney Disease Epidemiology (CKD-EPI) equation vs. the Cockcroft-Gault equation, should be used to estimate glomerular filtration rate in patients with atrial fibrillation treated with direct oral anticoagulants. Our review tries to find arguments for benefit of direct oral anticoagulants in patients with renal dysfunction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|